Deferoxamine is used in the treatment of?

MNS 2024

Pharmacology

Medium

Appeared in: MNS 2024

Explanation

Deferoxamine is an iron-chelating agent specifically designed to treat chronic iron overload (hemosiderosis).
Thalassemia major is a condition that requires lifelong, frequent blood transfusions to manage severe anemia.
These repeated transfusions lead to a significant accumulation of iron in the body, which is toxic to organs like the heart and liver.
Deferoxamine binds to this excess iron, forming a complex that is then excreted from the body, primarily through urine, thus preventing organ damage.

Option A: The primary treatment for aplastic anemia is immunosuppressive therapy or a bone marrow transplant to address the underlying bone marrow failure, not iron chelation.
Option C: The primary treatment for sickle cell anemia focuses on managing pain crises and reducing sickling with drugs like hydroxyurea. Iron overload is not the central problem as it is in transfusion-dependent thalassemia.
Option D: Megaloblastic anemia is caused by a deficiency in vitamin B12 or folic acid. The treatment is supplementation with the deficient vitamin, not iron removal.

Clinical Relevance

Nursing practice connection: Knowing Pharmacology and clinical application of Deferoxamine helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses play a crucial role in educating patients and families about the difficult, time-consuming nature of Deferoxamine administration (often a slow, overnight subcutaneous infusion) and the critical importance of adherence for survival.
Monitoring for and managing the side effects of Deferoxamine, such as injection site reactions, hypotension, and long-term sensory deficits (vision, hearing), is a key nursing responsibility.
What if? If a patient with thalassemia refuses their chelation therapy due to the discomfort of infusions, the nurse's priority is to explore the specific barriers, provide education on the life-threatening risks of untreated iron overload (like heart failure), and collaborate with the medical team to find alternatives, such as oral chelators (e.g., Deferasirox).

How to Approach the Question

First, identify the drug in the question: Deferoxamine.
Recall or deduce the drug's primary function. The 'fer' in the name is a clue related to iron. Deferoxamine is a classic iron-chelating agent.
Next, analyze the options, which are all types of anemia. Ask yourself: Which of these conditions is most strongly associated with iron overload?
Consider the pathophysiology of each anemia. Aplastic, sickle cell, and megaloblastic anemias have primary treatments that are not iron chelation.
Recognize that Thalassemia major requires chronic, lifelong blood transfusions. This inevitably leads to severe iron overload, making it the primary indication for iron chelation therapy among the choices.
Therefore, connect the drug's action (removing excess iron) with the disease that causes it (Thalassemia due to transfusions).

Concept Tested & Keywords

QNwbGbgP-KeR6P9aNzbQIx

E6 Pharmacology Katzung 16e p. 1604-1606

E6 Nelson Textbook of Pediatrics(2024) — Volume 2 pp. 776-778, 778-780